All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

risankizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	5337	1612838-76-2

Description:

Molecule	Description
Synonyms: risankizumab skyrizi BI655066 655066-01 ABBV-066 BI-655066 risankizumab-rzaa risankizumab (genetical recombination)	Skyrizi is a medicine used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. Indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
1.67	mg	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
March 26, 2019	PMDA	AbbVie Deutschland GmbH & Co KG
April 23, 2019	FDA	AbbVie INC
April 26, 2019	EMA	AbbVie Deutschland GmbH & Co KG

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
COVID-19	219.34	16.48	185	12579	168658	90447025
Maternal exposure during pregnancy	156.17	16.48	221	12543	359842	90255841
Surgery	147.68	16.48	87	12677	44800	90570883
Therapy interrupted	136.33	16.48	86	12678	50022	90565661
Death	131.11	16.48	232	12532	456319	90159364
Drug ineffective	126.55	16.48	453	12311	1383845	89231838
Product storage error	119.72	16.48	58	12706	20183	90595500
Intestinal obstruction	109.26	16.48	67	12697	37064	90578619
Ileocaecal resection	96.67	16.48	21	12743	531	90615152
Psoriasis	94.28	16.48	110	12654	147644	90468039
Inflammatory bowel disease	86.05	16.48	31	12733	5140	90610543
Breast cancer female	77.16	16.48	39	12725	14847	90600836
Abortion spontaneous	73.67	16.48	61	12703	53995	90561688
Urinary tract infection	68.53	16.48	140	12624	305492	90310191
Faecal calprotectin increased	66.71	16.48	24	12740	3963	90611720
Stoma creation	58.13	16.48	11	12753	135	90615548
Illness	57.26	16.48	64	12700	81905	90533778
Small intestinal obstruction	54.13	16.48	35	12729	21199	90594484
Ileal stenosis	49.42	16.48	17	12747	2461	90613222
Paternal exposure during pregnancy	48.70	16.48	11	12753	334	90615349
Device issue	48.06	16.48	37	12727	29500	90586183
Abdominal pain	47.78	16.48	143	12621	395578	90220105
Skin burning sensation	44.35	16.48	30	12734	19581	90596102
Large intestinal stenosis	41.66	16.48	15	12749	2482	90613201
Breast cancer	41.05	16.48	44	12720	53717	90561966
Erythema nodosum	38.72	16.48	18	12746	5706	90609977
Product temperature excursion issue	38.19	16.48	11	12753	892	90614791
Therapeutic response shortened	37.97	16.48	29	12735	22850	90592833
Arthralgia	37.84	16.48	212	12552	778310	89837373
Rheumatoid arthritis	36.97	16.48	4	12760	362610	90253073
Stenosis	36.58	16.48	13	12751	2071	90613612
Intestinal resection	35.77	16.48	14	12750	2913	90612770
Cerebrovascular accident	34.26	16.48	62	12702	123471	90492212
Erythema	33.66	16.48	89	12675	229157	90386526
Abdominal abscess	33.55	16.48	16	12748	5371	90610312
Unevaluable event	33.54	16.48	40	12724	54808	90560875
Hospitalisation	32.65	16.48	62	12702	128038	90487645
Pustule	32.47	16.48	13	12751	2870	90612813
Therapeutic product effect incomplete	32.33	16.48	79	12685	193817	90421866
Therapy cessation	31.79	16.48	32	12732	36329	90579354
Skin disorder	31.53	16.48	32	12732	36674	90579009
Pruritus	30.02	16.48	153	12611	541372	90074311
SARS-CoV-2 test positive	29.99	16.48	19	12745	11109	90604574
Wound	29.26	16.48	4	12760	302976	90312707
Drug interaction	28.30	16.48	3	12761	276450	90339233
Stomatitis	28.07	16.48	3	12761	274695	90340988
Live birth	27.62	16.48	44	12720	79063	90536620
Colectomy	27.25	16.48	12	12752	3355	90612328
Face oedema	27.04	16.48	24	12740	23294	90592389
Terminal ileitis	26.59	16.48	9	12755	1241	90614442
Infusion related reaction	26.18	16.48	13	12751	416767	90198916
Faecal calprotectin abnormal	26.11	16.48	6	12758	197	90615486
Gastrointestinal wall thickening	25.34	16.48	10	12754	2127	90613556
Intestinal dilatation	24.58	16.48	10	12754	2300	90613383
Dermatitis exfoliative generalised	24.24	16.48	13	12751	5580	90610103
Pyoderma gangrenosum	24.02	16.48	12	12752	4452	90611231
Anastomotic ulcer	23.91	16.48	7	12757	601	90615082
Palmoplantar pustulosis	23.85	16.48	7	12757	607	90615076
Device defective	23.70	16.48	11	12753	3475	90612208
Confusional state	22.85	16.48	13	12751	386192	90229491
Impaired healing	22.83	16.48	3	12761	234196	90381487
Ileostomy	22.67	16.48	9	12755	1945	90613738
Neuroendocrine tumour of the lung	22.27	16.48	4	12760	36	90615647
Mucous stools	22.14	16.48	12	12752	5259	90610424
Skin plaque	21.93	16.48	15	12749	9960	90605723
Myalgia	21.75	16.48	64	12700	175061	90440622
Psoriasis area severity index increased	21.23	16.48	5	12759	183	90615500
Renal surgery	21.18	16.48	5	12759	185	90615498
Exposure during pregnancy	21.10	16.48	4	12760	238406	90377277
Intestinal anastomosis	21.04	16.48	7	12757	915	90614768
Joint swelling	20.98	16.48	24	12740	503276	90112407
Swelling	20.93	16.48	17	12747	419041	90196642
Frequent bowel movements	20.33	16.48	32	12732	56903	90558780
Systemic lupus erythematosus	20.26	16.48	13	12751	361883	90253800
Mycobacterium tuberculosis complex test positive	20.15	16.48	9	12755	2603	90613080
Ileal ulcer	20.05	16.48	7	12757	1059	90614624
Intentional dose omission	20.02	16.48	18	12746	17765	90597918
General physical health deterioration	19.55	16.48	13	12751	355102	90260581
Obstruction	19.52	16.48	10	12754	3911	90611772
B-cell type acute leukaemia	19.48	16.48	6	12758	613	90615070
Wheezing	19.05	16.48	5	12759	238075	90377608
Small intestinal resection	18.94	16.48	6	12758	672	90615011
Tuberculosis	18.85	16.48	15	12749	12534	90603149
Vocal cord leukoplakia	18.58	16.48	3	12761	13	90615670
Hidradenitis	18.55	16.48	10	12754	4337	90611346
Uterine leiomyoma	18.53	16.48	14	12750	10850	90604833
Intentional product use issue	18.44	16.48	4	12760	216888	90398795
Exposure via breast milk	17.93	16.48	8	12756	2307	90613376
Perineal disorder	17.63	16.48	3	12761	19	90615664
Pericarditis	17.61	16.48	8	12756	270143	90345540
Cholecystectomy	17.55	16.48	14	12750	11741	90603942
Somnolence	17.49	16.48	4	12760	209080	90406603
Neutropenia	17.47	16.48	5	12759	224899	90390784
Pseudopolyp	17.44	16.48	5	12759	399	90615284
Contraindicated product administered	17.25	16.48	12	12752	320127	90295556
Anastomotic stenosis	17.22	16.48	5	12759	417	90615266
Injection site papule	17.19	16.48	6	12758	906	90614777
Fibromyalgia	17.14	16.48	4	12760	206265	90409418
Spinal operation	17.08	16.48	13	12751	10183	90605500
Lower respiratory tract infection	17.01	16.48	7	12757	250652	90365031
Diverticulitis	16.97	16.48	26	12738	45161	90570522
Folliculitis	16.91	16.48	4	12760	204349	90411334
Dermatopathic lymphadenopathy	16.80	16.48	3	12761	26	90615657
Decreased appetite	16.74	16.48	17	12747	376523	90239160
Nephrolithiasis	16.71	16.48	27	12737	49058	90566625
Thrombosis prophylaxis	16.70	16.48	3	12761	27	90615656
Stress	16.68	16.48	36	12728	81359	90534324

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ileostomy	149.89	17.97	38	10375	1080	42609842
Ileocaecal resection	123.99	17.97	27	10386	387	42610535
Psoriasis	123.19	17.97	99	10314	48505	42562417
Death	120.18	17.97	316	10097	470869	42140053
Ileal stenosis	112.79	17.97	34	10379	1850	42609072
Product storage error	104.24	17.97	52	10361	11088	42599834
Surgery	84.49	17.97	53	10360	17563	42593359
Intestinal obstruction	83.34	17.97	62	10351	27096	42583826
COVID-19	80.52	17.97	119	10294	115829	42495093
Stoma creation	73.12	17.97	14	10399	100	42610822
Drug ineffective	65.73	17.97	315	10098	629882	41981040
Colectomy	62.68	17.97	23	10390	2306	42608616
Small intestinal stenosis	61.59	17.97	18	10395	879	42610043
Dermatitis exfoliative generalised	59.88	17.97	29	10384	5795	42605127
Therapy interrupted	57.75	17.97	46	10367	22204	42588718
Therapeutic product effect decreased	52.64	17.97	56	10357	39094	42571828
Abdominal abscess	51.28	17.97	25	10388	5068	42605854
Ileectomy	50.35	17.97	11	10402	160	42610762
Angiolymphoid hyperplasia with eosinophilia	46.82	17.97	10	10403	130	42610792
Obstruction	46.23	17.97	20	10393	3083	42607839
Small intestinal obstruction	45.83	17.97	36	10377	17025	42593897
Gastrointestinal wall thickening	45.23	17.97	17	10396	1822	42609100
Gastrointestinal inflammation	44.62	17.97	22	10391	4570	42606352
Pruritus	42.10	17.97	121	10292	188650	42422272
Intestinal stenosis	41.54	17.97	18	10395	2786	42608136
Stenosis	39.56	17.97	16	10397	2085	42608837
Intestinal anastomosis	39.12	17.97	11	10402	467	42610455
Unevaluable event	39.09	17.97	45	10368	34243	42576679
Mycobacterium tuberculosis complex test positive	37.05	17.97	14	10399	1522	42609400
Osteosarcoma recurrent	36.58	17.97	8	10405	117	42610805
Arthralgia	35.98	17.97	121	10292	205117	42405805
Anastomotic stenosis	35.88	17.97	10	10403	411	42610511
Parenteral nutrition	35.62	17.97	11	10402	649	42610273
Small intestinal resection	35.31	17.97	11	10402	668	42610254
Abdominal pain	34.90	17.97	114	10299	190357	42420565
Proctectomy	34.87	17.97	8	10405	147	42610775
Product temperature excursion issue	34.46	17.97	10	10403	476	42610446
Intestinal resection	34.42	17.97	14	10399	1850	42609072
Lung neoplasm malignant	34.25	17.97	32	10381	19115	42591807
Prostate cancer	34.10	17.97	48	10365	44595	42566327
Basal cell carcinoma	33.20	17.97	34	10379	22699	42588223
Feeling of despair	32.77	17.97	12	10401	1196	42609726
Inflammation	31.37	17.97	40	10373	33807	42577115
Faecal calprotectin increased	30.58	17.97	15	10398	3079	42607843
Neutropenia	30.25	17.97	6	10407	199425	42411497
SARS-CoV-2 test positive	30.23	17.97	21	10392	8239	42602683
Colon cancer	29.45	17.97	22	10391	9659	42601263
Off label use	29.44	17.97	71	10342	638264	41972658
Knee arthroplasty	29.07	17.97	21	10392	8760	42602162
Skin plaque	29.00	17.97	18	10395	5845	42605077
Illness	28.89	17.97	33	10380	24897	42586025
Therapeutic response shortened	28.87	17.97	25	10388	13529	42597393
Laparotomy	28.70	17.97	8	10405	329	42610593
Ileocolostomy	27.01	17.97	5	10408	29	42610893
Postoperative abscess	26.77	17.97	8	10405	422	42610500
Tuberculosis	26.45	17.97	21	10392	10078	42600844
Hepatic cirrhosis	26.14	17.97	28	10385	19674	42591248
Acute kidney injury	25.96	17.97	31	10382	367306	42243616
Anastomotic ulcer	25.72	17.97	8	10405	483	42610439
Latent tuberculosis	25.68	17.97	11	10402	1654	42609268
Psoriatic arthropathy	25.53	17.97	31	10382	24936	42585986
Botryomycosis	25.39	17.97	5	10408	42	42610880
Skin burning sensation	25.00	17.97	18	10395	7469	42603453
Device issue	24.97	17.97	23	10390	13486	42597436
Thrombocytopenia	24.48	17.97	8	10405	190271	42420651
Ileal ulcer	24.21	17.97	9	10404	935	42609987
Somnolence	24.20	17.97	3	10410	141102	42469820
Peripheral arterial occlusive disease	24.12	17.97	17	10396	6821	42604101
Eczema	23.61	17.97	35	10378	34051	42576871
Jugular vein thrombosis	23.37	17.97	11	10402	2063	42608859
Abscess	22.06	17.97	22	10391	14226	42596696
Intestinal operation	21.98	17.97	6	10407	228	42610694
Rhinophyma	21.95	17.97	3	10410	0	42610922
Fistula	21.90	17.97	17	10396	7895	42603027
Enterocutaneous fistula	21.68	17.97	9	10404	1252	42609670
Colon operation	21.64	17.97	6	10407	242	42610680
Ostomy bag placement	21.49	17.97	4	10409	24	42610898
Therapeutic product effect incomplete	21.43	17.97	51	10362	70888	42540034
Neoplasm malignant	21.26	17.97	27	10386	22716	42588206
Prosthesis implantation	20.84	17.97	4	10409	29	42610893
Terminal ileitis	20.10	17.97	7	10406	603	42610319
Marginal zone lymphoma	20.03	17.97	5	10408	133	42610789
KL-6 increased	19.92	17.97	5	10408	136	42610786
Lung cancer metastatic	19.58	17.97	11	10402	2975	42607947
Cholangiocarcinoma	19.38	17.97	9	10404	1637	42609285
Frequent bowel movements	19.36	17.97	25	10388	21382	42589540
Myocardial infarction	18.99	17.97	70	10343	123939	42486983
Papillary cystadenoma lymphomatosum	18.95	17.97	4	10409	49	42610873
Dermatitis atopic	18.92	17.97	19	10394	12385	42598537
Confusional state	18.36	17.97	9	10404	167588	42443334
Squamous cell carcinoma	18.20	17.97	19	10394	12963	42597959
Hypereosinophilic syndrome	18.03	17.97	6	10407	450	42610472

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
COVID-19	270.71	15.49	253	16527	244807	110327712
Ileocaecal resection	216.41	15.49	42	16738	549	110571970
Therapy interrupted	195.10	15.49	111	16669	49711	110522808
Psoriasis	132.59	15.49	133	16647	139860	110432659
Intestinal obstruction	128.06	15.49	87	16693	53140	110519379
Death	127.68	15.49	308	16472	698561	109873958
Ileostomy	120.75	15.49	34	16746	2358	110570161
Ileal stenosis	118.77	15.49	36	16744	3234	110569285
Surgery	102.93	15.49	69	16711	41214	110531305
Colectomy	85.00	15.49	30	16750	4348	110568171
Abdominal abscess	74.14	15.49	33	16747	8786	110563733
Stenosis	72.91	15.49	25	16755	3326	110569193
Inflammatory bowel disease	70.36	15.49	30	16750	7204	110565315
Illness	65.08	15.49	71	16709	82100	110490419
Drug interaction	63.36	15.49	3	16777	500180	110072339
Unevaluable event	59.21	15.49	58	16722	59169	110513350
Abdominal pain	56.88	15.49	189	16591	512800	110059719
Urinary tract infection	56.33	15.49	141	16639	326141	110246378
Faecal calprotectin increased	56.03	15.49	25	16755	6694	110565825
Small intestinal obstruction	55.43	15.49	43	16737	32170	110540349
Intestinal stenosis	54.10	15.49	22	16758	4693	110567826
Stoma creation	53.59	15.49	11	16769	194	110572325
Product storage error	53.39	15.49	36	16744	21692	110550827
Angiolymphoid hyperplasia with eosinophilia	51.50	15.49	10	16770	131	110572388
Intestinal resection	50.87	15.49	20	16760	3909	110568610
Gastrointestinal inflammation	50.74	15.49	26	16754	9443	110563076
Small intestinal stenosis	50.03	15.49	15	16765	1298	110571221
Dermatitis exfoliative generalised	49.91	15.49	27	16753	10945	110561574
Ileectomy	49.49	15.49	11	16769	287	110572232
SARS-CoV-2 test positive	46.32	15.49	30	16750	16905	110555614
Gastrointestinal wall thickening	45.36	15.49	18	16762	3605	110568914
Small intestinal resection	43.41	15.49	13	16767	1120	110571399
Arthralgia	40.26	15.49	228	16552	779404	109793115
Anastomotic stenosis	40.21	15.49	11	16769	685	110571834
Osteosarcoma recurrent	38.61	15.49	8	16772	148	110572371
Skin plaque	38.57	15.49	24	16756	12621	110559898
Basal cell carcinoma	37.38	15.49	40	16740	45230	110527289
Proctectomy	37.30	15.49	9	16771	339	110572180
Intestinal anastomosis	36.93	15.49	11	16769	930	110571589
Prostate cancer	36.02	15.49	36	16744	37605	110534914
Anastomotic ulcer	35.38	15.49	11	16769	1075	110571444
Intervertebral disc protrusion	35.17	15.49	31	16749	27667	110544852
Neutropenia	33.23	15.49	8	16772	374612	110197907
Abortion spontaneous	33.19	15.49	33	16747	34249	110538270
Parenteral nutrition	33.08	15.49	10	16770	890	110571629
Postoperative abscess	32.86	15.49	10	16770	910	110571609
Hospitalisation	32.76	15.49	69	16711	142424	110430095
Pustule	32.33	15.49	14	16766	3490	110569029
Influenza	32.26	15.49	76	16704	169025	110403494
Intestinal operation	32.19	15.49	9	16771	608	110571911
Faecal calprotectin abnormal	32.08	15.49	8	16772	346	110572173
Off label use	31.80	15.49	119	16661	1500066	109072453
Hepatic steatosis	31.56	15.49	38	16742	48793	110523726
Dermatitis atopic	31.26	15.49	28	16752	25513	110547006
Cerebrovascular accident	30.88	15.49	78	16702	181206	110391313
Squamous cell carcinoma	30.37	15.49	24	16756	18439	110554080
Gallbladder operation	30.34	15.49	12	16768	2381	110570138
Prosthesis implantation	30.02	15.49	6	16774	92	110572427
Breast cancer female	29.07	15.49	20	16760	12448	110560071
Myocardial infarction	29.00	15.49	79	16701	192004	110380515
Diverticulitis	28.79	15.49	38	16742	53484	110519035
Confusional state	28.47	15.49	18	16762	468662	110103857
Device defective	28.01	15.49	13	16767	3809	110568710
Cellulitis	27.79	15.49	60	16720	125956	110446563
Stomatitis	27.74	15.49	4	16776	270238	110302281
Device issue	27.60	15.49	30	16750	34505	110538014
Rheumatoid arthritis	27.36	15.49	6	16774	299607	110272912
Somnolence	27.07	15.49	6	16774	297443	110275076
Lung cancer metastatic	26.85	15.49	13	16767	4185	110568334
Mycobacterium tuberculosis complex test positive	26.67	15.49	12	16768	3276	110569243
Thrombosis prophylaxis	26.23	15.49	5	16775	59	110572460
Neoplasm malignant	25.82	15.49	30	16750	37113	110535406
Nephrolithiasis	25.34	15.49	40	16740	66172	110506347
Sacroiliitis	24.75	15.49	13	16767	4965	110567554
Lung neoplasm malignant	24.64	15.49	28	16752	33814	110538705
Cholecystectomy	24.40	15.49	17	16763	10792	110561727
Peripheral arterial occlusive disease	24.30	15.49	16	16764	9264	110563255
Spinal operation	24.17	15.49	17	16763	10955	110561564
Malignant melanoma	23.66	15.49	20	16760	16871	110555648
Rhinophyma	23.38	15.49	3	16777	0	110572519
Terminal ileitis	23.31	15.49	9	16771	1675	110570844
Anal abscess	23.27	15.49	17	16763	11621	110560898
Cutaneous T-cell lymphoma	23.23	15.49	11	16769	3373	110569146
Anal fistula	23.14	15.49	15	16765	8458	110564061
Joint swelling	23.02	15.49	20	16760	442825	110129694
KL-6 increased	23.01	15.49	6	16774	311	110572208
Ear infection	22.78	15.49	37	16743	62695	110509824
Ileal ulcer	22.65	15.49	9	16771	1808	110570711
Pemphigus	22.43	15.49	3	16777	214567	110357952
Abscess	22.20	15.49	24	16756	27445	110545074
Colon cancer	22.08	15.49	19	16761	16424	110556095
Large intestinal stenosis	22.07	15.49	11	16769	3769	110568750
Hepatic cirrhosis	22.04	15.49	38	16742	67588	110504931
Cholangiocarcinoma	21.73	15.49	10	16770	2875	110569644
Breast cancer	21.71	15.49	28	16752	38514	110534005
Wheezing	21.57	15.49	6	16774	255224	110317295
Neuroendocrine tumour of the lung	21.41	15.49	4	16776	42	110572477
Infusion related reaction	21.33	15.49	16	16764	381146	110191373
Rectal stenosis	21.07	15.49	6	16774	433	110572086
Tuberculosis	20.80	15.49	19	16761	17755	110554764
Ostomy bag placement	20.77	15.49	4	16776	50	110572469
Thrombocytopenia	20.36	15.49	14	16766	348871	110223648
Papillary cystadenoma lymphomatosum	20.13	15.49	5	16775	213	110572306
Renal surgery	20.10	15.49	5	16775	214	110572305
Appendicitis	19.80	15.49	23	16757	28441	110544078
Colon operation	19.64	15.49	6	16774	553	110571966
Pruritus	19.57	15.49	153	16627	581407	109991112
Sinusitis	19.56	15.49	93	16687	296595	110275924
Marginal zone lymphoma	19.55	15.49	5	16775	240	110572279
Therapeutic product effect incomplete	19.24	15.49	76	16704	223729	110348790
Feeling of despair	19.12	15.49	10	16770	3788	110568731
Pityriasis rubra pilaris	18.94	15.49	5	16775	272	110572247
Botryomycosis	18.87	15.49	4	16776	83	110572436
Pustular psoriasis	18.84	15.49	16	16764	13589	110558930
Viral infection	18.83	15.49	31	16749	53108	110519411
Hidradenitis	18.82	15.49	11	16769	5169	110567350
Erythema nodosum	18.72	15.49	12	16768	6641	110565878
Psoriasis area severity index increased	18.63	15.49	5	16775	290	110572229
Cholelithiasis	18.56	15.49	34	16746	63388	110509131
Acrokeratosis paraneoplastica	18.55	15.49	3	16777	12	110572507
Jugular vein thrombosis	18.50	15.49	11	16769	5334	110567185
Mucous stools	18.40	15.49	12	16768	6835	110565684
Ileus	18.38	15.49	23	16757	30706	110541813
Face oedema	18.36	15.49	24	16756	33445	110539074
Pyoderma gangrenosum	18.25	15.49	11	16769	5465	110567054
Systemic lupus erythematosus	18.03	15.49	8	16772	254330	110318189
Medical device site inflammation	18.01	15.49	3	16777	15	110572504
Pelvic floor dysfunction	18.01	15.49	3	16777	15	110572504
Acute kidney injury	17.98	15.49	44	16736	635386	109937133
Obstruction	17.75	15.49	11	16769	5741	110566778
Cardiac disorder	17.59	15.49	37	16743	76243	110496276
Overdose	17.14	15.49	7	16773	233787	110338732
Small intestinal anastomosis	17.02	15.49	3	16777	22	110572497
Uterine leiomyoma	16.98	15.49	12	16768	7788	110564731
Frequent bowel movements	16.90	15.49	35	16745	71355	110501164
Osteochondrosis	16.71	15.49	8	16772	2513	110570006
Musculoskeletal stiffness	16.63	15.49	11	16769	279811	110292708
Fibromyalgia	16.48	15.49	3	16777	170906	110401613
Palmoplantar pustulosis	16.30	15.49	6	16774	980	110571539
Intra-abdominal fluid collection	16.28	15.49	9	16771	3805	110568714
Psoriatic arthropathy	16.25	15.49	66	16714	196695	110375824
Erythema	16.15	15.49	87	16693	291360	110281159
Folliculitis	16.04	15.49	3	16777	167650	110404869
Musculoskeletal pain	16.04	15.49	4	16776	183019	110389500
Inflammatory marker increased	16.03	15.49	15	16765	14454	110558065
Injection site papule	15.97	15.49	6	16774	1038	110571481
Skin burning sensation	15.79	15.49	18	16762	21807	110550712
Knee operation	15.75	15.49	11	16769	7011	110565508
Rash macular	15.68	15.49	24	16756	38662	110533857
Therapy cessation	15.66	15.49	26	16754	44831	110527688
Lithotripsy	15.62	15.49	3	16777	37	110572482
Myalgia	15.60	15.49	71	16709	222310	110350209
Pyelocaliectasis	15.56	15.49	6	16774	1113	110571406
Eye swelling	15.56	15.49	22	16758	33026	110539493

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC18	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
FDA MoA	N0000192798	Interleukin-23 Antagonists
FDA EPC	N0000192799	Interleukin-23 Antagonist
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:50177	dermatologic drug
CHEBI has role	CHEBI:50748	antipsoriatic
CHEBI has role	CHEBI:65023	anti-asthmatic agent
CHEBI has role	CHEBI:67079	anti-inflammatory agent

Related Drugs by ATC class:

L04AC Interleukin inhibitors 18 drugs

anakinrabasiliximabbimekizumabbrodalumabcanakinumabdaclizumabguselkumabixekizumabmirikizumabrilonaceptsarilumabsatralizumab show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Psoriasis	indication	9014002	DOID:8893
Palmoplantar pustulosis	indication	27520001	DOID:4398
Crohn's disease	indication	34000006
Psoriatic arthritis	indication	156370009	DOID:9008
Plaque psoriasis	indication	200965009
Pustular psoriasis	indication	200973000
Erythrodermic psoriasis	indication	200977004

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-23 subunit alpha	Cytokine	Q9NPF7	IL23A_HUMAN	INHIBITOR	Kd	11		SCIENTIFIC LITERATURE	DRUG LABEL

External reference:

ID	Source
90ZX3Q3FR7	UNII
4038346	VANDF
C4505511	UMLSCUI
CHEBI:756510	CHEBI
CHEMBL3990029	ChEMBL_ID
DB14762	DRUGBANK_ID
D11052	KEGG_DRUG
10128	INN_ID
C000601773	MESH_SUPPLEMENTAL_RECORD_UI
8922	IUPHAR_LIGAND_ID
787732000	SNOMEDCT_US
787746000	SNOMEDCT_US
314451	MMSL
36772	MMSL
36774	MMSL
d09243	MMSL
017980	NDDF
2166040	RXNORM

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-1050	INJECTION	150 mg	SUBCUTANEOUS	BLA	30 sections
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-2100	INJECTION	150 mg	SUBCUTANEOUS	BLA	30 sections
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-4059	INJECTION, SOLUTION	55 mg	SUBCUTANEOUS	BLA	30 sections
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-5015	INJECTION	600 mg	INTRAVENOUS	BLA	30 sections
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-8300	INJECTION	180 mg	SUBCUTANEOUS	BLA	30 sections
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-8350	INJECTION	180 mg	SUBCUTANEOUS	BLA	30 sections